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Abstract
Background: Glucocorticoids are often used in the treatment of nonhematologic malignancy.
This review summarizes the clinical evidence of the effect of glucocorticoid therapy on
nonhematologic malignancy.
Methods:  A systematic review of clinical studies of glucocorticoid therapy in patients with
nonhematologic malignancy was undertaken. Only studies having endpoints of tumor response or
tumor control or survival were included. PubMed, EMBASE, the Cochrane Register/Databases,
conference proceedings (ASCO, AACR, ASTRO/ASTR, ESMO, ECCO) and other resources were
used. Data was extracted using a standard form. There was quality assessment of each study. There
was a narrative synthesis of information, with presentation of results in tables. Where appropriate,
meta-analyses were performed using data from published reports and a fixed effect model.
Results: Fifty four randomized controlled trials (RCTs), one meta-analysis, four phase l/ll trials and
four case series met the eligibility criteria. Clinical trials of glucocorticoid monotherapy in breast
and prostate cancer showed modest response rates. In advanced breast cancer meta-analyses, the
addition of glucocorticoids to either chemotherapy or other endocrine therapy resulted in
increased response rate, but not increased survival. In GI cancer, there was one RCT each of
glucocorticoids vs. supportive care and chemotherapy +/- glucocorticoids; glucocorticoid effect
was neutral. The only RCT found of chemotherapy +/- glucocorticoids, in which the glucocorticoid
arm did worse, was in lung cancer. In glucocorticoid monotherapy, meta-analysis found that
continuous high dose glucocorticoids had a detrimental effect on survival. The only other evidence,
for a detrimental effect of glucocorticoid monotherapy, was in one of the two trials in lung cancer.
Conclusion: Glucocorticoid monotherapy has some benefit in breast and prostate cancer. In
advanced breast cancer, the addition of glucocorticoids to other therapy does not change the long
term outcome. In GI cancer, glucocorticoids most likely have a neutral effect. High dose continuous
glucocorticoids have a detrimental effect in nonhematologic malignancy. Glucocorticoid therapy
might have a deleterious impact in lung cancer.
Background
Glucocorticoids are frequently used in the treatment of
nonhematologic malignancy to relieve symptoms of can-
cer and its treatment. For example, glucocorticoids pre-
vent vomiting and allergic reactions associated with
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cancer therapy. Glucocorticoids decrease edema in CNS
malignancy, and can decrease pain secondary to cancer.
Glucocorticoids are part of the treatment of some cancers.
Glucocorticoids, as monotherapy and in combination
with ketoconazole or chemotherapy, are used in prostate
cancer. They are an option for postmenopausal women
with breast cancer. Thymomas are another indication for
glucocorticoids. Lymphoma and multiple myeloma can
respond to glucocorticoids.
The effect of glucocorticoids on the treatment of solid
tumors has been reviewed. In both reviews, the possibil-
ity, that combination therapy with glucocorticoids could
be detrimental, was raised. In both reviews, there was no
mention of prospective clinical studies [1,2].
Glucocorticoids are commonly used; the prospect of glu-
cocorticoids having an unfavorable effect on cancer ther-
apy has been brought up. With this in mind, a systematic
review was done of clinical research concerning glucocor-
ticoids in nonhematologic malignancy. The data regard-
ing the effects of glucocorticoids, as monotherapy and in
combination with other therapies (chemotherapy, hor-
monal therapy, radiotherapy, surgery), on nonhemato-
logic malignancy was studied. The purpose is to make
medical practice recommendations and suggest future
research directions.
Methods
All RCTs found of glucocorticoids in nonhematologic
malignancy that looked at any of the endpoints of tumor
response, tumor control (time to disease progression,
time to treatment failure, progression free survival) or
overall survival were included. A trial was considered ran-
domized if it was described as such in the manuscript. All
such trials that compared a glucocorticoid arm to a non-
glucocorticoid arm or compared two glucocorticoid arms
were included. All meta-analyses of such randomized con-
trolled trials were included. All phase l/ll trials found of
glucocorticoid monotherapy in nonhematologic malig-
nancy, other than breast or prostate cancer, were included.
All case series found of glucocorticoid monotherapy in
nonhematologic malignancy, other than breast cancer or
prostate cancer or thymoma, that contained tumor
response data were included. All case reports in nonhema-
tologic malignancy, that showed either tumor suppres-
sion or enhancement in response to glucocorticoid
monotherapy, were included. In breast cancer, prostate
cancer and thymoma, case reports of tumor shrinkage in
response to glucocorticoid monotherapy were excluded.
Trials, that were unpublished or published in abstract
form only, were included.
A literature search was performed using the National
Library of Medicine PubMed database (1950-September
25, 2007), EMBASE (1974–2007, week 38), Cochrane
Central Register of Controlled Trials (to third quarter
2007), Cochrane Database of Systematic Reviews (to third
quarter 2007), Cochrane Database of Abstracts of Reviews
of Effects (to third quarter 2007), ACP Journal Club
(1991-September/October 2007), Index Medicus
(1949–1965), Excerpta Medica (1947–1979), CINAHL
(1977-September Week 3 2007), and reference lists in
published papers. See Additional file 1 for the search strat-
egies of PubMed, EMBASE, the Cochrane Library (includ-
ing ACP Journal Club) and CINAHL. The Related Articles
feature of PubMed was used to search for additional arti-
cles. Science Citation Index was used to check for articles
citing the publications making up the systematic review.
Conference proceedings of AACR (1953–2007), ASCO
(1974–2007), ASTRO/ASTR (1977–2006), ESMO
(1977–2006), ECCO (1991–2005) and other relevant
conferences were hand searched. The National Guidelines
Clearinghouse was used to check for guidelines under the
disease category neoplasms available as of September 24,
2007. The literature was searched for randomized control-
led trials, meta-analyses, phase l/ll trials, other clinical
observational studies, practice guidelines and reviews
(systematic and nonsystematic). There was no language
restriction on the literature search. For some trials, authors
were contacted to obtain more information. Authors, who
had published more recently in this field, were contacted
to see if they were aware of any unpublished case series,
clinical trials or meta-analyses. Textbooks of medical
oncology, radiation oncology and palliative care were
reviewed to obtain further references. Ongoing trials (as of
September 27, 2007) were searched for at the Clinical Tri-
als section of the NCI website (cancer.gov) using the drug
names cortisone, dexamethasone, methylprednisolone,
prednisolone, prednisone and therapeutic hydrocorti-
sone.
The author determined the eligibility of the RCTs, meta-
analysis, phase l/ll trials, case series and case reports that
resulted from the search. Information, regarding trial
design, patient characteristics, therapy, results and quality
criteria were extracted from the eligible studies by the
author. Data was extracted using a standard form.
For RCTs, the quality criteria published by Jaddad et al
were used. In this instrument, 0 to 2 points are assigned
for randomization, 0 to 2 points are assigned for double
blinding and 0 to 1 points are assigned for the description
of withdrawals and dropouts. This gives a score ranging
from 0 to 5 with a higher score being better [3]. For phase
l trials, phase ll trials and case series, the quality criteria are
those described by the Centre for Reviews and Dissemina-BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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tion for case series [4]. No published quality criteria for
meta-analyses were found, so one was devised.
Information from the clinical trials, case series and the
meta-analysis is presented in tables, with the results being
synthesized in a narrative manner.
Where RCTs were similar enough in patient characteris-
tics, therapy and endpoints, meta-analyses were per-
formed. Response definitions were those used by the
authors of each RCT; only complete and partial responses
were included as responses. Followup was assumed to be
complete. Survival at selected time points was extrapo-
lated from graphs. If survival graphs were not provided,
exponential survival was assumed and the median sur-
vival was used to generate survival data. Within trials, the
response rates and survival in the two arms formed 2 by 2
tables for which odds ratios and their corresponding 95%
confidence intervals and between trial comparisons were
made using logistic regression. Homogeneity of the odds
ratios across trials was evaluated using a Breslow-Day χ2
test. Odds ratio estimates and between-group compari-
sons for the combined trials were made using the Mantel-
Haenszel fixed effect model. A result had to have a p value
of less than 0.05 to be considered statistically significant.
Results
Results of Literature Search
The literature was searched for clinical studies of glucocor-
ticoids. Studies were eligible if patients had nonhemato-
logic malignancy, and if there were endpoints of tumor
response or tumor control or survival. For RCTs and meta-
analyses, trials comparing two glucocorticoid arms or a
glucocorticoid arm to a nonglucocorticoid arm were eligi-
ble. After excluding duplicate publications of the same
trial, fifty four RCTs met the eligibility criteria ([5-54] and
[55-61]); one meta-analysis met the eligibility criteria
[62]. In nonhematologic malignancy other than breast or
prostate cancer, four phase l/ll (nonrandomized) trials of
glucocorticoid monotherapy were found [63-66]. In non-
hematologic malignancy other than breast cancer or pros-
tate cancer or thymoma, four case series of glucocorticoid
monotherapy with tumor response data were identified
[67-70]. One of the case series is a clinical trial; however,
tumor response rate was not a preplanned endpoint, so it
is presented as a case series [67]. Three clinical trials, with
no available results, were identified [71-73]. Nine case
reports of glucocorticoid monotherapy, other than breast
cancer or prostate cancer or thymoma regressing in
response to glucocorticoid monotherapy, were found [74-
83]. No article was excluded due to quality.
Glucocorticoids are commonly given as premedication
with chemotherapy to prevent nausea and vomiting. In
the chemotherapy trials mentioned in this review, there
are two trials where it is clear whether glucocorticoids
were used as premedication in patients not on the gluco-
corticoid arm [23,28]. In the other chemotherapy trials,
there is no mention of whether such usage was permitted
or not.
Case Reports
There are case reports of nonhematologic malignancy
either regressing or having increased growth in response
to glucocorticoids. It is reasonably well documented in
the literature that thymoma can sometimes respond to
glucocorticoids [84]. In melanoma, 2 doses of 100 mg of
intravenous hydrocortisone 8 hours apart caused tumor
lysis syndrome in a patient with melanoma [74]. There are
case reports where glucocorticoids apparently stimulated
the growth of melanoma [75,76]. There is a case report of
liver metastasis of thymic carcinoid responding to pred-
nisolone [77]. Metastatic renal cell carcinoma might have
shown a complete response to glucocorticoids in two
patients[78,79]. There are case reports where glucocorti-
coids apparently stimulated the growth of breast cancers
[80-83].
Case Series
The four case series of glucocorticoid monotherapy are
shown in Table 1[67-70]. They included patients with a
variety of cancers, such as lung cancer, GI cancer, breast
cancer and sarcoma. No tumor regression, objective
improvement or relief of pain was noted. Glucocorticoid
doses were not dissimilar taking into account relative glu-
cocorticoid activities (Table 2). For any particular tumor
type, the number of cases is small: the one exception is the
255 lung cancer patients in the case series of de Camp
[69].
With regards to quality, two case series were from tertiary
care centers; the two that were not originated from sec-
ondary care institutions [67,69]. Three of the four case
series had less than 50 patients [67,68,70]. None of the
case series were multi-institutional. Three of the four case
series did not describe eligibility criteria [68-70]. In one
case series, patients were similar with regards to the state
of cancer progression; in the other studies, not enough
information was provided to assess similarity [67]. In one
case series, followup was long enough to assess whether
glucocorticoids could cause cancer to decrease in size; in
the other studies, it was unclear if followup was sufficient
to assess this [70]. In none of the case series was reduction
in tumor size assessed using objective criteria.
Phase l and Phase ll (Nonrandomized) Trials
In phase l/ll (nonrandomized) trials, responses have been
noted. Based on responses lasting at least 28 days,
responses in the four trials were 0% [63], 6% [64], 6%
[65] and 6% [66]. In the largest trial (407 patients), 13 ofBMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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the 24 responses were in breast and prostate cancer with
the 2 complete responses being in breast and prostate can-
cer [66]. The next largest trial was 94 patients with no
responses [63]. The phase l/ll (nonrandomized) clinical
trials are presented in Table 3.
The two glucocorticoids used in these clinical trials were
fluorometholone and NSC-17256. Fluorometholone may
have progestational properties [22]. One hundred mg of
NSC-17256 is equivalent to 50–67 mg of prednisone;
however, it also has sex steroid properties.
With regards to quality, all the clinical trials were from ter-
tiary care centers. All clinical trials had more than 50
patients. Three of the four trials were multi-institutional
[63,65,66]. One of the trials did not describe eligibility
criteria [65]. In one trial, patients were similar with
regards to the state of cancer progression; in the other tri-
als, not enough information was provided to assess simi-
larity [64]. In two trials, followup was long enough to
assess whether glucocorticoids could cause cancer to
regress in size; in the other two trials, it was unclear if fol-
lowup was sufficient to assess this [64,66]. Reduction in
tumor size was assessed using objective criteria in three of
the studies [64-66]; this was unclear in the other study.
Randomized Controlled Trials of Glucocorticoids in the 
Endocrine Therapy of Advanced Breast Cancer
There are two types of trials in this category. In the first
type, glucocorticoids are given as monotherapy and com-
pared to other endocrine therapies given as monotherapy.
There are ten trials of this type, which tend to be small and
often use endocrine therapies that are no longer given. In
these trials, the vast majority of patients were postmeno-
pausal or enrolment was limited to postmenopausal
patients. The results show that glucocorticoids have mod-
est activity in postmenopausal women. A description of
these trials is given in Table
4[5,15,18,19,22,38,47,55,56]. The three earliest trials
used response criteria that are not readily comparable to
presently used response criteria [5,19,22].
The second type of trial is of an endocrine agent +/- gluco-
corticoids. These trials tend to be larger, more recent and
limited to women who are postmenopausal or who
received ovarian irradiation. There are four trials in this
category: three are of tamoxifen +/- glucocorticoids and
one is of aminoglutethimide +/- glucocorticoids. Results
are presented in Table 4[7,24,37,46]. As these trials were
more similar in nature, meta-analyses of response rates
and survival were undertaken. As seen in Figure 1, the
addition of glucocorticoids to another endocrine therapy
resulted in an increased response rate. Figure 2 shows that
this addition does not change one year survival rates.
However, there was evidence for a lack of homogeneity
among the four studies in Figure 2, as shown by the chi-
square test and its p value. The meta-analysis was
repeated, except that the trial which was furthest from the
other three trials in response rate and survival was omitted
[24]. The result of the omission was that the addition of
glucocorticoids did not change one year survival rates,
although the lack of homogeneity disappeared (odds ratio
of 0.91 95% CI 0.77–1.08, X2
2 = 3.389 p = 0.184).
One unpublished trial of hormonal therapy +/- glucocor-
ticoids, with no available results, was found [72].
Table 1: Case Series of Glucocorticoid Monotherapy
Author [reference], Year Patient Characteristics Treatment Responses
Postlethwait et al [68], 1951 4 gastric, 1 rectal, 1 gallbladder, 1 
esophageal, all advanced stage
300 mg IM of cortisone on day 1, 200 mg 
IM on day 2 then 100 mg IM daily for 21 
days; one patient received 150 mg instead 
of 100 mg
no objective improvement
de Camp [69], 1961 255 bronchogenic carcinoma, 19 primary 
lung tumors of other origins (sarcoma, 
adenomatosis etc.), 6 alveolar cell 
carcinoma of lung, 14 with cancer 
metastatic to lung, 26 pleural carcinoma, 2 
pericardial carcinoma
patients received 30–40 mg of prednisone/
prednisolone per day, which was tapered 
to 10–15 mg per day (occasionally to 5 mg 
per day) or 4 mg of dexamethasone per 
day tapered to 1–1.5 mg per day
no effect, either positive or negative
Plengvanit and Viranuvatti [70], 1964 7 primary carcinoma of the liver 40–60 mg of daily prednisone for 2 weeks 
to 10 months
little value as based on effect on pain and 
liver size (by physical examination)
Bruera et al [67], 1985 8 colon, 7 breast, 4 lung, 4 soft tissue 
sarcoma, 2 kidney, 2 prostate, 1 head and 
neck, 1 melanoma, 1 pancreas, 1 ovarian
methyprednisolone 16 mg po twice daily 
for 25 out of 34 days
no tumor regression







Dexamethasone 30BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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Randomized Controlled Trials of Glucocorticoids in the 
Endocrine Therapy of Breast Cancer in the Adjuvant 
Setting
In this setting, there are trials of endocrine therapy +/- glu-
cocorticoids and trials of glucocorticoid monotherapy
compared to no therapy: they are summarized in Table 5.
The trials of endocrine therapy +/- glucocorticoids consist
of two trials of tamoxifen +/- glucocorticoids in postmen-
opausal women; these trials are negative [6,9]. This is con-
sistent with the results from the advanced breast cancer
setting.
In the first of the two trials of glucocorticoid mono-
therapy, glucocorticoids weren't beneficial in the post-
menopausal group; they might have been beneficial in the
premenopausal group, who were treated with ovarian
irradiation [44]. In the second trial of glucocorticoid mon-
otherapy, premenopausal women were randomly treated
with chemotherapy or ovarian ablation followed by a sec-
ond randomization to glucocorticoids versus no glucocor-
ticoids. Regardless of whether a woman received
chemotherapy or ovarian ablation, glucocorticoids were
not beneficial. In the 81% of patient in whom ER status
was known, chemotherapy tended to be more effective
than ovarian ablation in those with low ER concentrations
whereas the opposite was true in those with higher ER
concentrations. No such relationship was noted when the
no prednisolone/prednisolone arms were compared [13].
One feature that complicates interpretation of the second
trial is that glucocorticoids were started at the time of
oophorectomy or at the start of chemotherapy, and were
to be given for 5 years unless relapse occurred. Those in
the chemotherapy arm got glucocorticoids during their 24
weeks of chemotherapy. This means that this trial could
also be considered a chemotherapy +/- glucocorticoids
trial. Glucocorticoid administration resulted in less bone
marrow suppression during chemotherapy [13].
Randomized Controlled Trials of Chemotherapy +/- 
Glucocorticoids in Advanced Breast Cancer
There are eight trials of chemotherapy +/- glucocorticoids
in advanced breast cancer [16,17,21,25,28,31,40,48];
results are presented in Table 6. Decreased thrombocyto-
penia [21,40] and increased administered chemotherapy
dose [21,40,48] were associated with glucocorticoid
administration in several of these trials.
In six of these trials, response rates are given; in four of
these trials, survival data is given. It was felt that there was
enough similarity in these trials to perform meta-analyses.
Meta-analyses of response rates and survival are presented
in Figures 3 and 4 respectively. The addition of glucocor-
ticoids to chemotherapy in the advanced breast cancer set-
ting resulted in an increased response rate. However, there
was no effect on one year survival.
Randomized Controlled Trials of Chemotherapy +/- 
Glucocorticoids of Breast Cancer in the Adjuvant Setting
There are two trials in this category. Both are relatively
large trials of CMF+/-prednisone, and both are negative.
This is consistent with what has been found in the
advanced breast cancer setting. At the time of enrolment,
none of the participants were postmenopausal. In com-
parison to trials that enroll postmenopausal women, this
might lessen the possible impact of glucocorticoids as
endocrine therapy. However, many women on these trials
subsequently developed amenorrhea. In the trial of
Tormey et al, 20% subsequently became postmenopausal.
In the trial of the Ludwig Breast Cancer Study Group, 85%
subsequently became postmenopausal. A description of
these trials is given in Table 7[12,53,85].
As in the randomized controlled trials of chemotherapy +/
- glucocorticoids in the advanced breast cancer setting,
there is evidence of decreased leukopenia [53], decreased
thrombocytopenia [12], increased chemotherapy dose
[53], and increased chemotherapy dose intensity [12] in
the glucocorticoid arms.
Table 3: Glucocorticoid Monotherapy Activity in Phase l and Phase ll (Nonrandomized) Trials
Author [reference], Year Patient Characteristics Treatment Responses
Mass [63], 1964 32 lung cancer (17 epidermoid, 7 adenocarcinoma, 8 
undifferentiated) 26 GI, 18 GU, 7 melanoma, 2 breast
25–100 mg flurometholone po per day 
for 7 weeks followed by taper
None
Moertel et al [64], 1964 18 colon, 13 gastric, 9 pancreatic, 5 carcinoid, 12 
primary unknown (presumed GI), 6 miscellaneous GI, 1 
renal cell
25 mg fluorometholone po every 12 hr 
for at least 2 months
4 PR (1 colon, 1 gastric, 2 primary 
unknown)
Johnson et al [65], 1966 44 melanoma, 9 lung carcinoma, 5 ovary, 4 uterus, 4 
prostate, 4 kidney, 4 breast, 7 miscellaneous
200–600 mg of NSC-17256 per day po 
for 8 weeks
melanoma (3 CR, 2 PR)
Ramirez et al [66], 1971 24 head and neck, 1 gastric, 36 colorectal, 2 pancreas, 
13 lung, 70 breast, 36 cervix, 12 uterus, 9 ovary, 9 
prostate, 27 kidney, 2 bladder, 111 melanoma, 1 
thyroid, 6 liver, 29 sarcoma, 11 primary unknown, 1 
lymphoma, 7 miscellaneous
200–600 mg of NSC-17256 per day po 
for 6 weeks; average dose 300 mg per 
day
Head and neck (1 PR), breast (1 CR, 8 PR), 
uterus/cervix (2 PR), ovary (1 PR), prostate 
(1 CR, 3 PR), melanoma (6 PR), Hodgkin (1 
PR)BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
Page 6 of 19
(page number not for citation purposes)
In one of the trials, there was a significant increase in
bone, alone or in combination with other sites, as the site
of first relapse in the chemotherapy plus prednisone arm
(relative risk of 2.06, 95% CI of 0.91 to 12.31, p = 0.09).
The authors postulated that the increased rate of bone
metastases as a first relapse site in this arm might be due
to cytokine inhibition, which might reduce a putative
anti-cancer process in bone, or to increased bone absorp-
tion [53].
Randomized Controlled Trials of Glucocorticoids in 
Prostate Cancer
In prostate cancer, there are two RCTs of glucocorticoids
in untreated patients [43,59]. Both are trials of orchiec-
tomy versus orchiectomy plus glucocorticoids versus
orchiectomy plus cyproterone acetate. The small numbers
enrolled preclude analysis, other than it is improbable
that glucocorticoids worsen outcome when added to
Table 4: Randomized Controlled Trials of Glucocorticoids in the Endocrine Therapy of Advanced Breast Cancer
Author [reference], Year Patient Characteristics Treatment Arms and Patient Numbers 
(Randomized/Evaluable)
Quality Score Outcome
Dao et al [19], 1961 postmenopausal, previous 
androgens or estrogens for 
advanced disease
bilateral adrenalectomy + hormone 
replacement (19/18) vs. cortisone acetate (at 
least 3 months; 300 mg on first day tapered to 
50 mg daily) (20/19)
1 8 vs. 0 remissions
Colsky et al [5], 1963 Postmenopausal 100 mg of 9α-bromo-11β-ketoprogesterone 
po every 8 hrs for at least 60 days (32/23) vs. 
same except 13.2 mg of prednisolone (23/18)
4 0 vs. 1 remission
Talley et al [22], 1964 postmenopausal, no previous 
endocrine therapy
10 mg of fluoxymesterone (an androgen) po 
twice daily (23/21) vs. 25 mg of oxylone 
acetate po twice daily (23/22)
2 3 vs. 6 remissions (ns)
Talley et al [22], 1964 postmenopausal, previous 
androgens or estrogens
25 mg of oxylone acetate po twice daily (14/
NR) vs. 12 mg of methylprednisolone twice 
daily (13/NR)
4 3 vs. 3 remissions
Gaertner et al [18], 1968 Postmenopausal dromostanolone propionate (an androgen) 
100 mg IM 3 times weekly (22/NR) vs. 
fluorometholone 25 mg po daily (22/NR) vs 
both together (24/NR)
3 9 vs. 2 vs. 5 responses
Goldenberg [15], 1969 postmenopausal, no previous 
hormonal therapy
Testololactone (an androgen) 75 mg twice 
daily po (103/100) vs. MPA 50 mg twice daily 
po (108/104) vs. oxylone acetate 25 mg twice 
daily po (108/107)
2 response rates of 4.9% vs. 9.3% vs. 
19.4%; p = 0.052 for MPA and oxylone 
being equal
Jakobsen et al [38], 1986 95% previous antiestrogen therapy, 
83% postmenopausal
prednisone 10 mg po three times daily (52/43) 
vs. MPA 500 mg po daily (48/38) vs. MPA 100 
mg IM daily except Sat/Sun for 3 weeks then 
500 mg IM weekly(50/40); continued until PD
1 response rates of 4.6% vs. 7.9% vs. 
12.5% (ns), median time to 
progression of 3 vs. 2.5 vs. 4 months 
(p = 0.09), median survival of 6 vs. 8.5 
vs. 10 months (p = 0.30)
Wander et al [56], 1987 81% postmenopausal, 40.5% ER and/
or PgR +ve, 26.7% ER/PgR -ve, 
32.8% ER/PgR unknown
aminoglutethimide 1000 mg po daily + 
cortisone acetate 50 mg po daily (65/62) vs. 
aminoglutethimide 1000 mg po daily + MPA 
1000 mg po daily (73/69)
1 response rates (CR/PR) of 6.5%/25.8% 
vs. 7.3%/24.6%
Kristensen et al, [47] 1992 Hypercalcemia due to breast cancer standardized isotonic saline + IV furosemide 
(15/15) vs. same + prednisolone 25 mg po 
three times daily for 8 days (15/15)
3m e d i a n  s u r v i v a l  o f  40 days vs. 84 days 
(p = 0.46)
Mercer et al, [55] 1993 postmenopausal; PD on tamoxifen 
(adjuvant or advanced setting)
aminoglutethimide 125 mg twice daily (28/27) 
vs. hydrocortisone 20 mg twice daily (33/29)
2 response rates in 11% vs. 21% (p > 
0.1), time to treatment failure similar 
(p = 0.743), overall survival similar (p 
= 0.240)
Stewart et al [24], 1982 Only previous systemic therapy 
allowed was adjuvant chemotherapy, 
98 ER +ve, 28 ER -ve, 54 ER 
unknown
Premenopausal: ovarian irradiation (19) vs. 
same + prednisolone 5 mg twice daily (16) 
Postmenopausal: tamoxifen 10 mg twice daily 
(72) vs. same + prednisolone 5 mg twice daily 
(73); treatment until PD; 204 randomized, 180 
evaluable
2 Premenopausal/Postmenopausal 
response rates: 21% vs. 44% (ns)/13% 
vs. 36% responses (p < 0.01), median 
survival 19 vs. 18 months (ns)/12 vs. 
21 months (p < 0.025)
Rubens et al [46], 1988 Only previous systemic therapy 
allowed was adjuvant chemotherapy 
(15%): ER/PgR unknown (23%) or 
ER+ve or PgR+ve
Premenopausal: ovarian irradiation with 
prednisolone 5 mg twice daily added on 
progression (NR/15) vs. ovarian irradiation + 
prednisolone 5 mg twice daily until PD (NR/
16)/Postmenopausal: tamoxifen 10 mg twice 
daily changed to prednisolone 5 mg twice daily 
on progression (NR/78) vs. tamoxifen 10 mg 
twice daily +prednisolone 5 mg twice daily 
until PD (NR/85); 220 randomized/194 
evaluable
2 Premenopausal/Postmenopausal 
response rates: 27% vs. 63% (p < 
0.05)/31%vs46%(p < 0.1), median time 
to disease progression: 4 vs. 14 
months (p = 0.006)/4 vs. 8 months (p 
= 0.02), median survival: 17 vs. 66 
months (p = 0.04)/17.5 vs. 21 months 
(p = 0.3)
Ingle et al, [7] 1991 postmenopausal; ER/PR unknown 
(15%) or ER+ve or PgR+ve; only 
previous systemic therapy allowed 
was adjuvant chemotherapy (7.8%)
tamoxifen 10 mg po twice daily (162/159) vs. 
tamoxifen 10 mg po twice daily + prednisolone 
5 mg po twice daily (164/161); continued until 
PD
5 responses in 38% vs. 47% (p = 0.15), 
median time to progression: 11 vs. 10 
months (p = 0.81), median survival: 35 
vs. 32 months (p = 0.40)
Cocconi et al, [37] 1992 postmenopausal; ER/PgR unknown 
(48%) or ER+ve or PgR+ve; no 
previous endocrine therapy for 
advanced disease; previous 
chemotherapy or endocrine therapy 
in 39%
aminoglutethimide 125 mg po twice daily for 1 
month then 250 mg po twice daily (84/78) vs. 
same + hydrocortisone 20 mg po twice daily 
(87/83); treatment until PD
3 responses in 41% vs. 44% (ns), median 
time to progression: 6.3 vs. 8.1 
months (p = 0.38), median survival: 
36.3 vs. 34.2 months (p = 0.56)BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
Page 7 of 19
(page number not for citation purposes)
orchiectomy. Both trials used response criteria that are not
readily comparable to presently used response criteria.
There are five randomized controlled trials of glucocorti-
coids in patients with hormone refractory prostate cancer
[8,32,33,35,36,54,60]. These are all trials comparing glu-
cocorticoid monotherapy to other monotherapies. When
Forest Plot of Response Rates of Endocrine Therapy +/- Glucocorticoids in Advanced Breast Cancer Figure 1
Forest Plot of Response Rates of Endocrine Therapy +/- Glucocorticoids in Advanced Breast Cancer.
Forest Plot of One Year Survival Rates of Endocrine Therapy +/- Glucocorticoids in Advanced Breast Cancer Figure 2
Forest Plot of One Year Survival Rates of Endocrine Therapy +/- Glucocorticoids in Advanced Breast Cancer.BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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glucorticoids are compared to other hormonal therapies
(progestational agents and flutamide), little difference
was noted. When glucocorticoids were compared to liaro-
zole (a retinoic acid stimulating agent), glucocorticoids
resulted in a better outcome. In the three oldest trials, the
response criteria used are not readily comparable to pres-
ently used response criteria [8,33,35].
There is one randomized controlled trial of chemotherapy
+/- glucocorticoids in prostate cancer [50]. This small trial 
Table 6: Randomized Controlled Trials of Chemotherapy +/- Glucocorticoids in Advanced Breast Cancer
Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Brambilla et al [17], 1974 Postmenopausal adriamycin 40–75 IV mg/m2 day 1, vincristine 
IV 1.4 mg/m2 days 1 and 8 every 3 weeks for 
8 cycles (20/15) vs same + prednisone 100 
po mg/m2/day days 1–5 (22/21)
2 response rates of 50% vs. 55%
Ramirez et al [16], 1975 5-fluorouracil (5-FU) 10 mg/kg/week IV, 
methotrexate 0.5 mg/kg/week IV, vincristine 
0.02 mg/kg/week IV, cyclophosphamide 2 
mg/kg/day po (NR/52) vs. same + 
prednisone po 45 mg/day for 2 weeks, then 
30 mg/day for 2 weeks then 15 mg/day (NR/
48); treatment until PD
2 response rates of 44.2% vs. 62.5% (p = 
0.075), no significant difference in 
response duration or survival
Rossi et al [25], 1976 Pre or postmenopausal, no 
previous chemotherapy
L-phenylalanine 4 mg/m2 po/day + 5-FU 300 
mg/m2 po/day each days 1–5 every 28 days 
(16/14) vs. same except 5-FU IV (18/18) vs. 
same as first except 5-FU IV + prednisone 
30 mg/m2/day days 1–5 (17/15)
1 response rates of 7% vs. 22% vs. 40% 
(ns)
Tormey et al [21], 1982 Pre or postmenopausal, no 
previous chemotherapy or 
prednisone therapy
CMF (NR/79) vs. CMFP (NR/86) vs. AV 
(NR/166); after 6 months or if progressive 
disease prior to then, switched to 
nonglucocorticoid containing chemotherapy
1 response rates of 57% vs. 63% vs. 56% 
(p > 0.10), response durations of 4.5 
months vs. 8.4 months vs. 7.7 months 
(p = 0.05), time to treatment failure of 
5.3 months vs. 9.1 months vs. 5.7 
months (p = 0.04), overall survival of 
14.5 months vs. 16.4 months vs. 13.7 
months (p = 0.03)
Tormey et al [48], 1983 Pre or postmenopausal, no 
previous chemotherapy or 
prednisone therapy
CMF (NR/47) vs. CMFP (NR/47) vs. rotation 
every 2 cycles between CMF and AV (NR/
50); treatment for 6 months followed by 
nonglucocorticoid containing therapy
2 response rates of 55% vs. 70% vs. 58% 
(ns), response duration of CMF less 
than CMFP (p = 0.39); time to 
treatment failure of CMF 5.6 months 
and CMFP 7.0 months (p = 0.16); 
median survival of CMF 12.5 months 
and CMFP 18.0 months
Gercovich et al [31], 1989 Untreated 5-FU + cyclophosphamide + mitoxantrone 
vs. same + prednisone 80 mg po days 1–5 
(53/50 in total)
1 no difference in response rates
Tashiro & Nomura [40], 1995 resistant to or relapsed after 
adriamycin treatment, pre or 
postmenopausal
mitomycin C 4 mg/m2 + methotrexate 35 
mg/m2 IV + vincristine 0.7 mg/m2 IV days 1 
and 8 every 21 days (21/21) (MMV) vs. same 
+ prednisolone 10 mg po per day (MMVP) 
(43/41) vs. same as first + MPA 1200 mg po 
per day (MMVM) (44/40); treatment until 
PD
2 response rates of 9.5% vs. 29% vs. 
37.5% (p = 0.0784 comparing MMV to 
MMVP); median duration of response 
of 12 vs. 16 vs. 34 weeks (ns); time to 
progression for MMVM longer than 
MMVP which was longer than MMV (p 
= 0.0256); survival differences (p = 
0.382)
Piccart et al [28], 1997 One previous chemotherapy 
regimen for advanced or metastatic 
breast cancer
docetaxel 50 mg/m2 IV days 1 and 8 every 3 
weeks (42/41) vs. same + 
methylprednisolone 40 mg po on days -
1,0,1,7,8 and 9 (41/39)
2 no significant differences in median 
response duration, median time to 
progression or median survival
Table 5: Randomized Controlled Trials of Glucocorticoids in the Endocrine Therapy of Breast Cancer in the Adjuvant Setting
Author [reference], 
Year
Patient Characteristics Treatment Arms; Patient Number (Randomized/
Evaluable)
Quality Score Outcome(s)
DiMartino et al [9], 
1991
Postmenopausal Tamoxifen 40 mg per day vs. same + prednisolone 7.5 mg 
per day; 67/57 vs. 49/47; treatment until recurrence
1 p values of 0.6743 and 0.2367 for 
differences in disease free survival and 
overall survival respectively
Fentiman et al [6], 
1994
Postmenopausal Tamoxifen 20 mg daily vs. same + prednisolone 7.5 mg 
daily; 186/173 vs. 184/168
2 p values of 0.26 and 0.32 for differences in 
relapse free survival and overall survival 
respectively
Meakin et al, [44], 1996 no further treatment (NT) vs. ovarian irradiation (R) vs. 
(if ≥ 45) ovarian irradiation + prednisolone 7.5 mg daily 
up to 5 years (R +P); Premenopausal (≥ 45 years old) 64 
vs. 71 vs. 73/Postmenopausal 136 vs. 111 vs. 111; 779 
randomized, 703 analyzed as above
1 Premenopausal(≥ 45 years old)/
Postmenopausal; median recurrence free 
survival (yrs): 9.4 vs. 18 vs. > 25/6.2 vs. 8.2 
vs. 6.8; median survival (yrs): 12.8 vs. 14.9 
vs. >25/9.3 vs. 9.9 vs. 7.7
Scottish Cancer Trials 
Breast Group [13], 
1993
Premenopausal ER+ve 
54%, ER status 
unknown 19%
Second randomization to prednisolone 7.5 mg po daily 
for 5 years vs. no prednisolone after first randomization 
to ovarian ablation vs. CMF (IV); 165/NR vs. 167/NR in 
second randomization
3 prednisolone effect did not depend on 
whether CMF or ovarian ablation (p = 
0.46); hazard ratio and 95% CI for deaths 
for +/-prednisolone was 1.26 (0.86–1.84)BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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Forest Plot of Response Rates of Chemotherapy +/- Glucocorticoids in Advanced Breast Cancer Figure 3
Forest Plot of Response Rates of Chemotherapy +/- Glucocorticoids in Advanced Breast Cancer.
Forest Plot of One Year Survival Rates of Chemotherapy +/- Glucocorticoids in Advanced Breast Cancer Figure 4
Forest Plot of One Year Survival Rates of Chemotherapy +/- Glucocorticoids in Advanced Breast Cancer.BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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has been published in abstract form only; it is difficult to
draw conclusions based on the information presented.
See Table 8 for a description of these trials.
There are two ongoing randomized controlled trials of
chemotherapy +/- glucocorticoids in hormone refractory
prostate cancer; results are not available [71,73].
Randomized Controlled Trials of Glucocorticoids in GI 
Cancer
There is one trial comparing glucocorticoid monotherapy
to placebo in GI cancer; no difference in survival was
found [26].
There are two trials of chemotherapy +/- glucocorticoids
in GI cancer [11,20]. One of the two trials used response
criteria that are not readily comparable to those presently
used. In that trial, fluorometholone monotherapy had a
response rate of 9%. The addition of fluorometholone to
5-FU did not change the response rate of 13% [20]. In the
other trial of chemotherapy +/- glucocorticoids (FUDR +/
- dexamethasone), the addition of glucocorticoids
resulted in an increased response rate and a borderline
improvement in survival (p = 0.06). However, FUDR
dose, as the mean percentage of planned FUDR dose, was
61% and 52% in the FUDR/dexamethasone arm and
FUDR arm respectively (p = 0.13). At least in part, the
increased dose of FUDR in the FUDR/dexamethasone arm
was due to the decreased biliary toxicity associated with
concurrent dexamethasone administration resulting in
less FUDR dose reductions. The chemoprotective property
of dexamethasone, allowing a greater FUDR dose, may
have contributed to the improved results in the combined
arm [11]. Other postulated reasons are a potentiation of
FUDR cytotoxicity by dexamethasone and a potential
antiangiogenic property of dexamethasone [86,87].
Table 8: Randomized Controlled Trials of Glucocorticoids in Prostate Cancer
Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Sander et al [43], 1982 Advanced untreated prostate 
cancer
orchiectomy (7/7) vs. ochiectomy + 
prednisone 2.5 mg po four times daily for 6 
weeks (14/14) vs. ochiectomy + cyproterone 
acetate 50 mg po four times daily for 6 weeks 
(13/13)
1 response rates of 86% vs. 93% vs. 62%
Williams et al [59], 1990 Advanced untreated prostate 
cancer
orchiectomy (24/24) vs. orchiectomy + 
dexamethasone 0.5 mg in morning and 0.3 mg 
at night (16/16) vs. orchiectomy + cyproterone 
acetate 100 mg 3 times daily (20/20)
3 response rates of 33% vs. 62.5% vs. 45% 
at 1 year
Fossa et al [33], 1985 Hormone refractory prostate 
cancer
MPA 500 mg po twice daily (24/21) vs. 
prednisolone 5 mg po four times daily (24/24)
2 response rates of 38% vs. 13% (p < 0.05), 
no survival difference
Patel et al [8], 1990 Hormone refractory metastatic 
prostate cancer
Megestrol acetate 40 mg po four times daily 
(29/25) vs. dexamethasone 0.75 mg po twice 
daily (29/26), Treatment until PD
2 response rates of 10% vs. 7%, median 
survival of 268 vs. 246 days (p = 0.2)
Datta et al [35], 1997 Hormone refractory metastatic 
prostate cancer
Flutamide 250 mg three times daily (20/20) vs. 
prednisolone 5 mg twice daily (20/20)
2 PSA response rates of 50% vs. 55%, 
median survival of 30 vs. 36 weeks (p > 
0.05)
Tyrrell [36, 54, 60], 1996 Hormone refractory advanced 
prostate cancer
prednisone 10 mg po twice daily (103/NR) vs. 
liarozole 300 mg po twice daily (117/NR)
1 PSA response rates of 25% vs. 18% (p = 
0.31); time to PSA progression of 4.7 vs. 
3.5 months; median survivals of 15.8 
months vs. 11.7 months (p = 0.01)
Fossa et al [32], 2001 Hormone refractory metastatic 
prostate cancer
prednisone 5 mg po four times a day (101/95) 
vs. flutamide 250 mg po three times a day (100/
96); treatment until PD
2 PSA responses of 21% vs. 23%, median 
time to progression of 3.4 months vs. 2.3 
months (p = 0.0885); overall survival of 
10.6 months vs. 11.2 months (p = 
0.8370)
Tombal et al [50], 2003 Hormone refractory metastatic 
prostate cancer
irofulven (24 mg/m2 for first 18 patients then 
0.55 mg/kg for next 43 patients) IV days 1 and 
15 q4 weeks (29/28) vs. same + prednisone 10 
mg daily (32/28)
1 PSA responses of 3/28 vs. 5/28
Table 7: Randomized Controlled Trials of Chemotherapy +/- Glucocorticoids of Breast Cancer in the Adjuvant Setting
Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Tormey et al [12], 1990 Premenopausal, ER+ve 51%, ER-
ve 49%,
CMF (222/188) vs. CMFP (220/183) vs. CMFP 
+ tamoxifen 10 mg po twice daily(220/182), all 
treatments for one year
2 median time to relapse: CMF 6.2 months 
vs. CMFP 6.6 months (p = 0.64), survival: 
CMF vs. CMFP (p = 0.91)
Ludwig Breast Cancer Study 
Group [53, 85], 1985
pre and peri-menopausal, ER 
+ve 28%, ER -ve 24% ER 
unknown 48%
CMF (250/241) vs. CMF + prednisone 7.5 mg 
daily (255/250), all treatments for one year
3 13 year disease-free survival of 52% vs. 
49% (p = 0.39), 13 year overall survival of 
65% vs. 59% (p = 0.30)BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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There are two trials of preoperative glucocorticoids in
patients scheduled to undergo esophagectomy; there was
no effect on survival [51,58].
A description of the GI trials is given in Table 9.
Randomized Controlled Trial of Glucocorticoids in 
Patients with Primary CNS Neoplasms
The one RCT of glucocorticoids in primary CNS neo-
plasms is described in Table 10. This trial uses a higher
dose of glucocorticoids than any other trial described in
this review; however, administration was on an intermit-
tent, rather than a continuous, basis. This trial compared
methyprednisolone versus BCNU versus BCNU plus
methylprednisolone versus procarbazine. The addition of
methylprednisolone to BCNU had a neutral effect on sur-
vival. Infection was significantly greater in the BCNU plus
methylprednisolone arm than the other arms; informa-
tion on the type and severity of infection is not available.
The mean number of courses of chemotherapy was iden-
tical in the BCNU and BCNU + methylprednisolone arms.
The mean radiotherapy dose +/- SE (rads) was 5701 +/- 79
in the methylprednisolone arm and 5589 +/- 96 in the
BCNU + methylprednisolone arm [23].
Randomized Controlled Trials of Glucocorticoids in 
Patients with GU Neoplasms
No trials were found in this category.
Randomized Controlled Trials and Meta-analysis of 
Glucocorticoids in Patients with a Variety of Cancers
There are five randomized controlled trials of glucocorti-
coid monotherapy in patients with a variety of cancers;
these trials are dissimilar in nature.
The first two trials used glucocorticoid doses higher than
any other trial in this review, with the exception of the pre-
viously mentioned randomized controlled trial in CNS
neoplasms. However, glucocorticoid administration was
continuous in these two trials. Also, administration was
intravenous; the bioavailability of oral methypred-
nisolone is 82% [88]. The two trials are very similar,
except that enrolment was limited to females with the sec-
ond trial [30,39]. With this in mind, a survival meta-anal-
ysis was performed, with the results presented in Figure 5.
Figure 5 shows that this high dose continuous gluccorti-
coid schedule had a detrimental effect on mortality. In the
first trial, the cause for the difference in mortality was
unknown. In the second trial, there were significantly
more gastrointestinal and cardiovascular adverse events in
the glucocorticoid arm; the severity and outcome of these
events did not significantly differ. Infectious complica-
tions occurred in 11.8% of the treated patients and 14.8%
of the placebo patients [39].
The third trial consists mostly of GI patients, and com-
pared indomethacin to prednisolone to placebo. The
results suggest that prednisolone might have a beneficial
effect on survival [14].
The fourth trial compares a progestational agent to dex-
amethasone to an androgen; no difference in survival was
observed. The patients were mostly lung and GI cancer
patients. Fifty three percent and twenty percent of the
patients had planned concurrent chemotherapy and radi-
ation therapy respectively.
The fifth trial compares opioids to opioids plus dexame-
thasone; no survival difference was found. This was a
Table 9: Randomized Controlled Trials of Glucocorticoids in GI Cancer
Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Moertel et al [26], 1974 GI cancer with expected survival of 
less than 2 months (61 colorectal, 
22 gastric, 15 pancreatic, 9 
hepatoma, 10 other)
placebo (47/NR) vs. dexamethasone 0.75 
mg four times daily (33/NR) vs. 
dexamethasone 1.5 mg four times daily (36/
NR); treatment until death or patient 
unable to take pills
3 Median survival (weeks) of 6.6 vs. 6.2 
vs. 5.2
Reitemeier et al [20], 1967 advanced GI cancer (37 gastric, 23 
pancreatic, 52 unknown but 
presumed GI in origin)
fluorometholone 25 mg po every 12 hour 
for at least 2 months (34/32) vs. 5-FU IV 15 
mg/kg/day for 5 consecutive days then 7.5 
mg/kg/day every other day for a maximum 
of 4 additional doses (40/40) vs. 5-FU plus 
fluorometholone as just described (38/32)
3 response rates of 9% vs. 13% vs. 
13%; average duration of response of 
4 vs. 6.5 vs. 4 months
Kemeny et al [11], 1992 untreated colorectal cancer with 
only metastases being in liver
hepatic arterial FUDR 0.3 mg/kg/day for 14 
of every 28 day cycle (25/25) vs. same plus 
hepatic arterial dexamethasone 20 mg over 
14 days with the FUDR (25/24)
3 response rates of 40% vs. 71% (p = 
0.03), median time to progression of 
12 vs. 19 months (p = 0.58), median 
survival of 15 vs. 23 months (p = 
0.06)
Sato et al [51], 2002 patients with esophageal squamous 
cell carcinoma scheduled to 
undergo esophageal resection
surgery (33/33) vs. surgery + 10 mg/kg 
methyprednisolone IV within 30 minutes of 
start of surgery (33/33)
5 p = 0.4465 for difference in overall 
survival rates 1 and 3 yr survival 
rates of 85% and 65% vs. 82% and 
62% respectively
Yano et al [58], 2005 patients with thoracic esophageal 
cancer scheduled for 
esophagectomy
surgery (20/20) vs. surgery + 
methylprednisolone 500 mg IV 2 hours 
before surgery (20/20)
3 p = 0.3304 for difference in survival 
ratesBMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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group of patients with very advanced cancer; no patient
lived longer than 45 days [61].
There is a meta-analysis of three small RCTs of glucocorti-
coids in patients with bowel obstruction secondary to
malignancy. The treatment period in these 3 trials lasted
from 3–10 days; after the treatment period, glucocorti-
coids were not prohibited. There was no survival differ-
ence [62].
There are two trials of chemotherapy +/- glucocorticoids.
In the older of these two trials, glucocorticoids had a neu-
tral effect. In this trial, the remission criteria are not read-
ily comparable to those presently used [27]. In the second
trial, glucocorticoids ameliorated the GI toxicity of perifo-
sine resulting in longer duration of treatment in the gluco-
corticoid arm: glucocorticoids may have acted as a
chemoprotective agent [52].
Finally, there is one trial of radiation +/- glucocorticoids in
patients with epidural metastases of a carcinoma com-
pressing the spinal cord or cauda equina [29]; there is a
second trial comparing two doses of glucocorticoids in
patients with spinal cord compression [57]. In both of
these trials, a large proportion of patients had breast or
prostate cancer. There was no survival difference in either
trial.
About the quality of the meta-analysis, the inclusion crite-
ria were objective and explicit. The literature search was
thorough. There was quality assessment of the clinical tri-
als that made up the meta-analysis. There was independ-
ent data abstraction by two reviewers. Individual patient
data was used to obtain survival analysis. However, the
meta-analysis is based on the results of 83 patients [62].
A description of these trials and the meta-analysis is given
in Table 11.
Forest Plot of Eight Week Mortality Rates in Two Trials of Glucocorticoid Monotherapy in Nonhematologic Malignancy Figure 5
Forest Plot of Eight Week Mortality Rates in Two Trials of Glucocorticoid Monotherapy in Nonhematologic 
Malignancy.
Table 10: Randomized Controlled Trial of Glucocorticoids in Primary CNS Neoplasms
Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Green et al [23], 1983 after surgery for supratentorial 
malignant glioma; 6000 rads of 
radiation to start concurrently with 
medical therapy
BCNU 80 mg/m2/day IV for 3 consecutive 
days every 8 weeks (147/124) vs. 
methylprednisolone 400 mg/m2/day orally 
for 7 consecutive days every 4 weeks (156/
141) vs. BCNU + methylprednisolone as 
previously described (153/134) vs. 
procarbazine 150 mg/m2/day orally for 28 
consecutive days every 8 weeks (153/128)
2 24 month survivals of 19.5% vs. 8.0% 
vs. 18.0% vs. 22.2%; in pairwise 
comparisons, only differences giving p 
< 0.05 were BCNU vs. 
methylprednisolone and procarbazine 
vs. methylprednisoloneBMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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Randomized Controlled Trials of Glucocorticoids in Lung 
Cancer
There are two randomized controlled trials of glucocorti-
coid monotherapy in lung cancer [10,41,42], with both
being described in Table 12. In the first trial, those in the
glucocorticoid arm did worse than those in the placebo
arm. As causes of death, rates of pulmonary infection,
hemorrhage, heart failure and perforated ulcer were very
similar between the placebo and cortisone arms. The
authors stated that they were unable to explain why the
cortisone arm did worse [41]. In a later publication
regarding this trial, it is noted that results were not differ-
ent between patients, who had received prior to the trial,
surgery, radiation therapy or who hadn't received either
therapy. Although it is unclear how systematically this was
studied, the authors did not observe a difference in the
rate of cancer progression between the placebo and corti-
sone arms based on x-ray and autopsy information [42].
The second trial is a comparison of prednisolone versus
megestrol acetate; those in the megestrol acetate arm did
significantly worse [10]. As mentioned in Table 12, no
radiation with a curative intent or chemotherapy was
given in the second trial (F. Macbeth, personal communi-
cation).
In lung cancer, there are two randomized controlled trials
of chemotherapy +/- glucocorticoids; both are included in
Table 12. The first trial was of cyclophosphamide +/-pred-
nisolone; the addition of prednisolone resulted in a lower
response rate and decreased survival. Of the planned
cyclophosphamide doses, 88% were administered in the
cyclophosphamide arm and 69% were administered in
the combined arm. As for treatment delays, 4 patients
were delayed 1–2 weeks with 3 of these being in the cyclo-
phosphamide arm. No patient died of treatment in the
cyclophosphamide arm, but 3 died of infection in the
combined arm. Six patients had infections requiring hos-
pitalization in the cyclophosphamide arm, compared to 2
in the combined arm. There was no significant difference
in hematologic toxicity between the 2 arms. There was a
trend for less leukopenia in the combined arm. In the
cyclophosphamide arm, a leukocyte count of less than
1999 cells/mm3 occurred in 43% of patients in cycle 1,
96% in cycle 2 and 100% in cycle 3. In the combined arm,
comparable data is 28% in cycle 1, 60% in cycle 2 and
Table 11: Randomized Controlled Trials of Glucocorticoids and Meta-analysis in Patients with a Variety of Cancers
Author [reference], 
Year
Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Della Cuna et al 
[30], 1989
preterminal carcinoma; male (196): 38.8% lung, 
12.8% stomach, 11.2% buccal cavity and pharynx, 
7.1% prostate, 5.1% rectum/rectosigmoid junction 
female (207): 34.8% breast, 10.1% stomach, 11.1% 
large intestine, 7.7% cervix uteri, 5.3% lung, 5.3% 
rectum/rectosigmoid junction
methylprednisolone 125 mg IV daily for 8 
weeks (207/NR) vs. placebo (196/NR)
5 mortality at 8 weeks: males 
40.2% vs. 35.5%, females 40.0% 
vs. 27.7% (p < 0.01)
Popiela et al [39], 
1989
terminal cancer, female, 85% with gastrointestinal or 
breast or genitourinary cancers, only solid tumors
methylprednisolone 125 mg IV daily for 56 
days (85/NR) vs. placebo (88/NR)
5 mortality at 56 days of 38% vs. 
30% (p > 0.05)
Lundholm et al [14], 
1994
liver/pancreas 44, colorectal 30, gastric 18, 
esophagus 15, melanoma 7, breast 3, head and neck 
3, miscellaneous 15
indomethacin 50 mg po twice daily (45/NR) 
vs. prednisolone 10 mg po twice daily (45/
NR) vs placebo (45/NR); all treatments until 
death
2 when all 3 groups compared 
simultaneously, survival of 
indomethacin > prednisone > 
placebo (p < 0.07)
Loprinzi et al [49], 
1999
40% lung cancer, 36% GI cancer, no breast or 
prostate or ovarian or endometrial cancer;
megestrol acetate 800 mg po every day 
(NR/158) vs. dexamethasone 0.75 mg po 
four times daily (NR/158) vs. 
fluoxymesterone 10 mg po twice daily (NR/
159)
2 median survival of 126 days 
with no statistically significant 
difference between the 3 arms
Mercadante et al 
[61], 2007
advanced cancer patients on strong opioids opioids vs. opioids + dexamethasone 8 mg 
po daily; 76 randomized/66 evaluable
2 Mean survival (range) of 33 
(26-40) vs. 37 (28-45) days
Feuer et al [62], 
1999, Metaanalysis
patients with bowel obstruction due to malignancy; 
vast majority either gynecological or GI cancer
glucocorticoids (65/54) vs. no 
glucocorticoids (32/29)
Kaplan-Meier survival curves 
and 1 month survival: no 
differences of statistical 
significance
Horton et al [27], 
1966
19 colorectal cancers, 13 adenocarcinomas of other 
primary sites, 10 miscellaneous cancers
5-FU IV 15 mg/kg on 1st, 2nd, 3rd, 4th and 6th 
days and 7.5 mg/kg every other day 
thereafter until diarrhea, stomatitis or 
leukopenia (21/NR) vs. same + 
methyprednisolone 24 mg po daily (21/NR)
4 response rates of 24% vs. 19%
Bernhardt et al [52], 
2006
cancers of lung (9), prostate (7), pancreas (3), ovary 
(2), breast (1), other (4)
docetaxel 75 mg/m2 day 8 of each 21 day 
cycle + perifosine 50 mg po 1 or 2 or 3 
times a day in successive cohorts on days 1-
14 vs. same + prednisone 5 mg twice daily
1 2 SD (2 prostate) in 7 evaluable 
patients vs. 3 PR (1 lung and 2 
prostate) and 1 SD (prostate) 
in 9 evaluable patients
Sorensen et al [29], 
1994
patients with compression of spinal cord or cauda 
equina due to cancer: 34 breast cancers, 6 GI 
cancer, 5 prostate cancer, 3 lung cancer, 4 sarcoma, 
2 melanoma, 1 each of kidney, mesothelioma and 
thyroid
radiation (30/30) vs. radiation + initial dose 
of dexamethasone 96 mg IV followed by 
dexamethasone 96 mg po daily for 3 days 
followed by 10 day taper (29/27)
2 median survival of 6 months in 
both arms
Graham et al, [57], 
2006
patients with spinal cord compression not due to 
lymphoma or myeloma: 11 breast or prostate 
cancer, 9 lung or GI or renal or other
radiation + 16 mg of dexamethasone 
intravenously for 3 days followed by 13 day 
taper (9/9) vs. same except 96 mg of 
dexamethasone for first 3 days (11/11)
1 median survivals of 2.4 vs. 2.1 
monthsBMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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77% in cycle 3 [34]. In the second trial of chemotherapy
+/- glucocorticoids, patients were given four cycles of
chemotherapy. Those in the chemotherapy + glucocorti-
coid arms (cohorts 2 and 3) received dexamethasone with
the last three cycles; cohort 1 received only chemotherapy.
Neutropenia and thrombocytopenia were significantly
decreased by the use of glucocorticoids [89].
Discussion
As monotherapy, glucocorticoids are thought to have
activity in breast cancer, prostate cancer and thymoma.
The evidence found in this review is consistent with that.
In Table 2, no responses were observed in case series data.
Although the quality of this generally older data is not
comparable to that from present clinical trials, it is
unlikely that major changes went undetected. In Table 3,
there is mention of responses in cancers other than breast,
prostate or thymoma in clinical trial data. However,
responses in these older trials were determined by physi-
cal examination and xrays. If present day imaging had
been used in these trials, it would not have been surpris-
ing if response rates were lower than those given. In one
trial, it was postulated that some tumor responses may
have been a consequence of anti-inflammatory activity,
rather than anti-tumor activity [64].
A postulated mechanism of action of glucocorticoids in
prostate cancer is adrenal androgen suppression [90]. For
breast cancer, postulated mechanisms are adrenocortical
inhibition and interaction with glucocorticoid receptors
[91]. The one breast cancer trial which looked at whether
there was a correlation between ER status and the effect of
glucocorticoids did not find one [13]. This lack of correla-
tion suggests that glucocorticoid therapy does not act
through the ER receptor. If this is true, a patient's men-
strual status may be important with regards to the effec-
tiveness of glucocorticoids. This is relevant, because some
of the RCTs of glucocorticoids in breast cancer, especially
the chemotherapy trials, included premenopausal
women.
Meta-analyses of endocrine therapy +/- glucocorticoids in
advanced breast cancer were undertaken. An increased
response rate was noted, but there was no improvement
in survival. A previous meta-analysis of tamoxifen +/-
other endocrine therapy in metastatic breast cancer has
been published [92]. This meta-analysis included two of
the four papers used in the meta-analysis presented in this
publication. The previously published meta-analysis also
showed an improved response rate, but no improvement
in survival
There was heterogeneity noted in the survival meta-analy-
sis of endocrine therapy +/- glucocorticoids in advanced
breast cancer. A critical variable in response to endocrine
therapy is ER/PR status. In the four older trials used in that
meta-analysis, one trial enrolled patients regardless of ER/
PR status [24]. In all four trials, patients of unknown
receptor status were enrolled; the percentage of patients
with unknown receptor status was as high as 47% [37].
Receptor heterogeneity may explain in part the observed
statistical heterogeneity.
Meta-analyses of chemotherapy +/- glucocorticoids in
advanced breast cancer were undertaken. Once again, an
increased response rate was noted, but no improvement
in survival. The meta-analysis of tamoxifen +/- other
endocrine therapy in metastatic breast cancer also
Table 12: Randomized Controlled Trials of Glucocorticoids in Lung Cancer
Author [reference], Year Patient Characteristics Treatment Arms
Patient Number (Randomized/Evaluable)
Quality Score Outcome(s)
Wolf et al [41, 42], 1960 lung carcinoma not amenable to 
surgery or radiation therapy; 
distribution of the 4 tumor types 
(squamous, small cell, 
adenocarcinoma, large cell) between 
treatment groups did not statistically 
differ
Nitrogen mustard 0. 4 mg/kg IV days 1 and 42 
(80/70) vs. testosterone propionate 100 mg IM 
three times weekly (106/99) vs. cortisone 100 
mg po daily (86/78) vs. progesterone 2 mg po 
daily (91/83) vs. diethylstilbestrol 10 mg po 
daily (89/82) vs. placebo po daily (88/84); all 
treatments (except for nitrogen mustard) for 
12 weeks followed by 8 week taper for oral 
treatments
4 median survival (days) of 121 vs. 78 
vs. 56 vs. 60 vs. 75 vs. 93
Macbeth et al [10], 1994 nonsmall cell and small cell lung 
cancer
76/72 to either megestrol acetate 480 mg/m2 
or prednisolone 15 mg/m2 for 8 weeks; no 
radiation with a curative intent or 
chemotherapy given
2 survival worse in the megestrol 
acetate arm (p = 0.02)
Thatcher et al [34], 1982 metastatic nonsmall cell and small 
cell lung cancer; no previous 
chemotherapy or steroids
Cyclophosphamide IV 1.5 g/m2, 2.5 g/m2, 3.5 g/
m2 each separated by 3 weeks (28/28, 16 
SCLC) vs. same + prednisolone 100 mg/m2 
orally on day of and day after each 
chemotherapy (29/29, 16 SCLC)
2 response rates of 57% vs. 24%, 
median duration of response 
(weeks) of 15 vs. 11 (p > 0.05), 
median survival (weeks) of 24 vs. 
14 (p = 0.004)
Leggas et al [89], 2005 untreated Stage lV NSCLC 4 cycles of carboplatin AUC 5.5 day 1 and 
gemcitabine 1000 mg/m2 days 1 and 8 every 21 
days; 4 days prior to and the day of each 
chemotherapy treatment in courses 2-4, 
dexamethasone 16 mg bid (NR/12) vs. 8 mg 
bid (NR/12) vs none (NR/6)
8 PR vs. 7 PR vs. 2 PRBMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
Page 15 of 19
(page number not for citation purposes)
included a meta-analysis of chemotherapy +/- endocrine
therapy. That meta-analysis did not include any of the six
trials included in this publication's meta-analysis of
chemotherapy +/- glucocorticoids. The meta-analysis of
chemotherapy +/- endocrine therapy similarly showed an
improved response rate, but no change in survival [92].
In several breast cancer trials of chemotherapy +/- gluco-
corticoids, there was increased chemotherapy dose
administered and less hematologic toxicity in the arms
receiving glucocorticoids. The information presented in
the results section may underestimate these effects, as tri-
als in which there were nonsignificant differences are not
mentioned. This decreased hematologic toxicity is consist-
ent with the known effects of glucocorticoids on the
hematopoeitic system [93]. In the RCTs of chemotherapy
+/- glucocorticoids of breast cancer in the adjuvant setting,
increased chemotherapy dose/dose intensity and
decreased hematologic toxicity did not translate into
improved outcomes. However, the two trials reporting
this were trials of 12 months of chemotherapy [12,85].
With such prolonged chemotherapy, cumulative dose and
dose intensity may be less important. Glucocorticoids are
commonly given with chemotherapy to patients with
metastatic breast cancer as antiemetics; they may be doing
more than preventing nausea and vomiting in some
patients.
In prostate cancer, glucocorticoids are used in combina-
tion with other endocrine therapy (ketoconazole) and
chemotherapy. The evidence for this is not strong. If the
breast cancer results are applicable to prostate cancer, it is
debatable whether such combination therapy is of bene-
fit.
The RCTs of glucocorticoids in GI cancer would suggest
that the effect of glucocorticoids is neutral. However, GI
cancer includes a diverse group of cancers; one cannot
exclude the possibility that glucocorticoids might not
have a neutral effect in a particular type of GI cancer. The
trial of Lundholm et al is presented in Table 11 because
patients with a variety of cancer were eligible; however,
79% of the patients had GI cancer. In that trial, there is a
suggestion that glucocorticoids might improve outcome
[14].
There were two trials of high dose continuous glucocorti-
coids compared to placebo in patients with nonhemato-
logic malignancy. There was only one other randomized
controlled trial which used a glucocorticoid dose that was
greater than the dose used in those two trials. In that trial,
patients were on glucocorticoids only one quarter of the
time [23]. When the results of the two trials of high dose
continous glucocorticoids were combined in a meta-anal-
ysis, there was a detrimental effect of glucocorticoids on
mortality. This raises the possibility that glucocorticoids,
at sufficient dose, may have an adverse effect on patients
with nonhematologic malignancy. This is especially rele-
vant to patients with primary and secondary CNS malig-
nancy, where doses of 16 mg per day of dexamethasone
are used.
It also raises the question of what is a safe dose of gluco-
corticoids in patients with nonhematologic malignancy.
The answer to this may in part depend on the site of origin
of the cancer. In GI cancer, dexamethasone 6 mg daily
appears to be safe [26]. In lung cancer, 100 mg daily of
cortisone may be unsafe [41]. In the two trials of continu-
ous high dose glucocorticoids, a considerable portion of
the patients had breast cancer. In one of the two trials, sur-
vival was analyzed according to the origin of the cancer.
When the treatment and placebo groups were compared
in these analyses, no differences of statistical significance
were observed [39].
The only other evidence of glucocorticoids, resulting in a
worse outcome than those in the placebo/best supportive
care arm, is in the single trial of lung cancer. This 1960
publication gives limited statistical detail. However, it
appears that the difference between the glucocorticoid
arm and the placebo arm had a p value of 0.02. It is diffi-
cult to explain the worse outcome on the dose of gluco-
corticoid given, as the daily dose was 100 mg of cortisone
[41].
The only trial of chemotherapy +/- glucocorticoids, in
which the glucocorticoid arm did worse, is in lung cancer.
There was a nonsignificant trend for decreased leukopenia
in this trial [34]. Others have observed decreased granulo-
cytopenia [94,95] and decreased thrombocytopenia [94]
when glucocorticoids are given with chemotherapy in
lung cancer patients. In the lung cancer trial of cyclophos-
phamide +/- prednisone, the authors postulated that the
differences found between the 2 arms might be due to the
effect of prednisone on the metabolism of cyclophospha-
mide; however, they themselves noted that both the ani-
mal and human data on this effect are conflicting. In the
trials of chemotherapy +/- glucocorticoids in breast can-
cer, a number of the trials included cyclophosphamide as
part of CMF. The dose of glucocorticoids given in the lung
cancer trial of chemotherapy +/- glucocorticoids is not
greatly different than the dose given commonly as an
antiemetic to lung cancer patients on chemotherapy.
It cannot be ruled out that glucocorticoids have an effect
on the newer targeted therapies. Glucocorticoids are com-
monly given with monoclonal antibodies. A postulated
mechanism of action of one of those antibodies, trastuzu-
mab, is via antibody-dependent cellular cytotoxicity [96].BMC Cancer 2008, 8:84 http://www.biomedcentral.com/1471-2407/8/84
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There is evidence that glucocorticoid may inhibit anti-
body-dependent cellular cytotoxicity [97].
There are limitations to the meta-analyses presented in
this study. Firstly, there may be unpublished randomized
controlled trials that are not included. Secondly, survival
was extrapolated from summary graphs and data, and the
point estimates are not as accurate as those that could
have been derived from the individual patient data.
Thirdly, the number of trials and the number of patients
in each trial tended to be small; this makes heterogeneity
more likely. For each meta-analysis, a chi-square test was
used to assess heterogeneity. However, a chi-square test
has low power if there are few trials or sample sizes are
small.
There is evidence that glucocorticoids have an effect on
the natural history of some nonhematologic malignan-
cies. However, that is not the only source of glucocorti-
coids that a cancer is exposed to. One's own body
synthesizes endogenous glucocorticoids. This raises the
question of what effect endogenous glucocorticoids have
on nonhematologic malignancy. The possible effect of
endogenous glucocorticoids on lung cancer is the subject
of another review (manuscript in preparation).
Breast cancer, prostate cancer and possibly lung cancer
show sensitivity to glucocorticoids. There may be variabil-
ity within cancers of each type in their sensitivity. This
raises the issue of predictive factors, that might assist in
assessing glucocorticoid sensitivity. Glucocorticoid recep-
tor status or histologic subtype (in lung cancer) might be
relevant. A genomic/proteomic approach to explore this
possibility might be useful.
Conclusion
The effect of glucocorticoids in nonhematologic malig-
nancy depend on the primary tumor site. Glucocorticoids
have a beneficial effect in breast and prostate cancer as
monotherapy. In combination with chemotherapy or
other endocrine therapy in breast cancer; glucocorticoids
increase response rate, but do not change survival. In GI
cancer, they most likely have a neutral effect. High dose
continuous glucocorticoids, in patients with nonhemato-
logic malignancy, decrease survival. Such treatment
should be avoided in patients with nonhematologic
malignancy. Based on ASCO criteria, this is a grade B rec-
ommendation based on level ll evidence. In lung cancer,
glucocorticoids might have a deleterious effect by them-
selves and when given with chemotherapy. It is recom-
mended that glucocorticoid use in lung cancer patients be
kept to the minimum required. This is a grade B recom-
mendation based on level ll evidence.
List of Abbreviations
AV: adriamycin 60 mg/m2 IV day 1 and vincristine 1.2 mg/
m2 IV day 1 every 21 days, BCNU: carmustine, CI: confi-
dence interval, CMF: cyclophosphamide 100 mg/m2 po
daily days 1–14 and methotrexate 40 mg/m2 IV days 1 and
8 and 5-FU 600 mg/m2 IV days 1 and 8 every 28 days,
CMFP: CMF and prednisone 40 mg/m2/day days 1–14,
CR: complete response, ER: estrogen receptor, 5-FU: 5-
fluorouracil, FUDR: fluorodeoxyuridine, IM: intramuscu-
lar, IV: intravenous, m2: meters squared, MPA: medroxy-
progesterone acetate, -ve: negative, ns: not significant, NR:
not reported, NSC-17256: 6α-methylpreg-4-ene-3,11,20-
trione, NSCLC: nonsmall cell lung cancer, PD: progressive
disease, +ve: positive, PR: partial response, PgR: progester-
one receptor, po: by mouth, SCLC: small cell lung cancer,
SD: stable disease, SE: standard error, vs.: versus
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